Table 2.
Study endpoints in men and subgroups of postmenopausal and fertile women of the intent-to-treat population treated with frovatriptan or the comparators
| Men (n = 66) | Postmenopausal women (n = 56) | Fertile women (n = 224) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Frovatriptan | Comparators | p value | Frovatriptan | Comparators | p value | Frovatriptan | Comparators | p value | |
| Pain free at 2 h (%) | 52/164 (32) | 64/167 (38) | NS | 56/173 (32) | 64/180 (36) | NS | 188/650 (29) | 211/644 (33) | NS |
| Pain relief at 2 h (%) | 62/123 (56) | 70/123 (57) | NS | 76/137 (56) | 82/148 (55) | NS | 294/531 (55) | 300/528 (57) | NS |
| Relapse at 24 h (%) | 5/52 (10) | 19/64 (30) | <0.05 | 9/56 (16) | 18/64 (28) | NS | 24/188 (13) | 45/211 (21) | <0.05 |
| Relapse at 48 h (%) | 11/52 (21) | 25/64 (39) | <0.05 | 20/56 (36) | 24/64 (38) | NS | 48/188 (26) | 86/211 (41) | <0.01 |
Data are shown as absolute values (number of attacks with the event and total number of attacks evaluated) and relative frequencies (%)